Federated Hermes Inc. Trims Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Federated Hermes Inc. cut its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,063,526 shares of the company’s stock after selling 144,774 shares during the quarter. Federated Hermes Inc. owned approximately 5.86% of IDEAYA Biosciences worth $130,133,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the fourth quarter valued at $35,000. Quantbot Technologies LP acquired a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at about $83,000. Daiwa Securities Group Inc. lifted its position in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after purchasing an additional 853 shares during the last quarter. KBC Group NV grew its stake in IDEAYA Biosciences by 84.6% in the fourth quarter. KBC Group NV now owns 4,197 shares of the company’s stock worth $108,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in IDEAYA Biosciences in the third quarter valued at about $213,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wedbush reaffirmed an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Stephens reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Trading Down 5.5 %

NASDAQ IDYA opened at $14.71 on Friday. The company has a 50-day moving average price of $20.05 and a two-hundred day moving average price of $25.11. IDEAYA Biosciences, Inc. has a 52 week low of $14.40 and a 52 week high of $44.42. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -4.46 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.